Welcome to our dedicated page for Adm Tronics news (Ticker: ADMT), a resource for investors and traders seeking the latest updates and insights on Adm Tronics stock.
ADM Tronics Unlimited, Inc. (OTCQB: ADMT) specializes in the design, development, and manufacturing of electronic medical devices for diagnostic and therapeutic applications at its FDA-registered facility. ADMT stands out as a one-stop source offering complete services including design, engineering, regulatory, and manufacturing, enabling seamless transition from concept to production. This integrated approach sets ADMT apart from firms that provide only partial services.
ADMT's expertise encompasses a range of proprietary medical devices in various fields such as audiology, physical medicine, wound therapy, neurology, and urology. Their notable projects include the development of the Vet-Sonotron®, a non-invasive pain treatment device for veterinary applications, and the ongoing work towards launching a human version. The Vet-Sonotron has shown remarkable efficacy in treating musculoskeletal pain without the need for drugs, signaling a significant advancement in veterinary and potentially human medicine.
Financially, ADMT has demonstrated robust growth with significant increases in net income and revenue across its operating segments which include Electronics, Engineering, and Chemical. For the nine months ended December 31, 2022, ADMT reported net income of $155,148, reversing a net loss of $140,221 from the previous year, driven by a 31% increase in revenues. They continued this positive trend into fiscal 2023 with a sustained increase in revenue and profit despite challenges in raw material supply.
ADMT's commitment to innovation is evidenced by its ongoing investment in research and development. The company recently expanded its capabilities with the introduction of the IonoJet™ by Origin Life Sciences, a plasma-generated nitric oxide device, developed in partnership with ADMT. This device aims to address fungal infections and chronic wounds, showcasing ADMT's versatility and expertise in medical technology development.
Headquartered in Northvale, NJ, ADMT operates with a multidisciplinary team of engineers, researchers, and technologists, utilizing state-of-the-art infrastructure. Their comprehensive approach ensures the delivery of effective and innovative medical solutions. For more information, visit admtronics.com.
ADM Tronics (OTCQB:ADMT) reported financial results for Q2 FY2025. Revenues increased 12% to $1,697,881 for the six months ended September 30, 2024, compared to $1,516,821 in the same period last year. The company posted income from operations of $118,423 versus a loss of $365,446 in the prior year period. For Q2, revenues grew 11% to $840,036, though operating loss was $45,858 compared to a $228,105 loss last year. The improvement was driven by increased revenues in engineering and chemical segments. The company continues R&D on its proprietary non-invasive musculoskeletal pain therapy device, planning an FDA 510(k) submission.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) reports positive financial results for the first quarter of Fiscal Year 2025 ended June 30, 2024. Key highlights include:
- Revenue increased by 12% to $857,845 compared to $762,689 in the same period last year
- Net profit of $272,168, a significant improvement from a net loss of $132,261 in the previous year
- Profit from operations of $164,281, compared to a loss of $137,796 in the same quarter last year
- Gross profit increased to $520,903 from $325,142
ADMT completed R&D for its Vet-Sonotron® device and is advancing the human medical version. The company plans to pursue FDA 510(k) submission for the human Sonotron®, targeting non-drug pain treatment.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) reported results for fiscal year ended March 31, 2024. Key highlights:
- Revenues decreased 19% to $2,965,406
- Gross profit fell to $1,116,422 (38% margin) from $1,657,902 (45% margin)
- Net loss widened to $877,222 from $96,322
- R&D expenses increased to $576,903 from $541,184
- Focused on finalizing Vet-Sonotron® technology for veterinary market
- Developing medical version of Sonotron® for human use
- Reduced engineering services revenues due to prioritizing proprietary product development
- Recorded reserve for past due accounts receivables
- Faced challenges from inflation and supply chain issues
FAQ
What is the current stock price of Adm Tronics (ADMT)?
What is the market cap of Adm Tronics (ADMT)?
What services does ADMT provide?
What is the Vet-Sonotron®?
How has ADMT performed financially?
What are ADMT’s areas of activity?
Where is ADMT headquartered?
What recent projects has ADMT undertaken?
What makes ADMT unique in the medical device industry?
What is ADMT's approach to research and development?
Who can benefit from ADMT’s services?
How can I get more information about ADMT?
